Elsevier’s Oncology Journal Network Highlights
Welcome to our Elsevier’s Oncology Journal Network Highlights page. Here you can browse through the latest, cutting-edge oncology and cancer biology research, our topical article collections, and learn more about our Network offerings.
November celebrates Carcinoid Cancer, Gastric Cancer, Lung Cancer, and Pancreatic Cancer Awareness Month.
Carcinoid Cancer
Neoplasia
Gastric Cancer
Critical Reviews in Oncology/Hematology
Clinics
Clinical Colorectal Cancer
Cancer Letters
Neoplasia
International Journal of Radiation Oncology*Biology*Physics
Lung Cancer
Critical Reviews in Oncology/Hematology
Clinics
Seminars in Oncology
Journal of the National Cancer Center
Clinical Lung Cancer
Journal of Liquid Biopsy
Cancer Letters
Neoplasia
International Journal of Radiation Oncology*Biology*Physics
Journal of Thoracic Oncology
JTO Clinical and Research Reports
Pancreatic Cancer
Clinics
Critical Reviews in Oncology/Hematology
Clinical Colorectal Cancer
Cancer Letters
Neoplasia
International Journal of Radiation Oncology*Biology*Physics
Forthcoming Special Issues
Advances in Cancer Biology - Metastasis
There are currently 3 special issues open for submission.
Revisiting RAS - another tough nut that's being cracked by cancer research
RAS is one of the recent ‘hot topics’ in translational cancer research because there is reason for hope that the undruggable RAS no longer is undruggable thanks to major developments in drug design. Due to the crucial role of RAS in malignant transformation, progression and metastasis these new achievements likely have the potential to become a ‘game-changer’ in cancer drug treatment.
This thematic issue will cover the field of research in the RAS oncogene in full breadth and depth. Starting with an introduction into the basics and history of RAS cancer biology it will then continue to RAS controlled signaling pathways and networks followed by an overview on regulation of RAS by microRNAs and epigenetic mechanisms. Next, crucial aspects of RAS in cancer cell biology including autophagy, exosomes, EMT, metastasis, and cell metabolism will be dealt with. Eventually, novel developments in drugging oncogenic RAS in cancer cells using recently developed and designed molecular target compounds will be explained, and an outlook on possible future strategies for effectively turning off RAS in precision medicine will be given.
Guest Editors:
Dr. Ira Skvortsova (Medical University of Innsbruck)
Dr. Simona Kranjc Brezar (Institute of Oncology Ljubljana)
Send us your pre-submission query(opens in new tab/window)
Bioinformatic Analysis of High-Throughput Molecular Data in Translational Oncology
Enormous amount of cancer related high-throughput molecular data has become publicly available in past decade and accumulation of new data is ongoing extensively. While there are “gold standard” techniques in data pre-processing and quality control, high data complexity makes interpretation challenging. Simultaneous analysis of genomic, transcriptomic, epi-transcriptomic, and proteomic data enables development of complex combinational biomarkers of tumor prognosis and therapy resistance. Numerous available bioinformatic tools and packages may be used for that, however there is an unmet need for approaches utilizing integrative analysis of complex cancer datasets. Such approaches may be based on machine learning methods; however, data standardization and unification are of paramount importance for that.
This special issue will be devoted to development of new and integration of existing bioinformatical methods for high-throughput analyses of cancer datasets with a focus on development of promising biomarkers.
Guest Editor:
Dr. Maxim Sorokin (Sechenov University, Russia)
Send us your pre-submission query(opens in new tab/window)
Unravelling Cancer Metastasis
This special issue will focus on basic and translational research of the features and mechanisms of cancer cells and their microenvironment that drive invasion and metastatic spread of tumors. What are the current strategies for treatment of cancer metastasis? We will address the differences and characteristics of the microenvironment of the primary tumor and distant organ cancer metastasis. We know that primary and metastatic tumors have unique microenvironment, thus it is important to identify genetic changes in metastatic tumors that can be further characterized as therapeutic targets. What are the key signaling pathway and cell interactions that lead to cancer metastasis? The special issue will also focus on immune response and its role in cancer metastasis. Furthermore, the issue will address clinical challenges in prevention and treatment of the cancer metastasis and what are the values and limitations of current tumor models to study metastasis.
Guest Editors:
Metka Novak, PhD ([email protected])
Barbara Breznik, PhD ([email protected])
Advances in Radiation Oncology
There are currently 2 special issues open for submission.
Radiopharmacology
The Advances editors are delighted to announce that in 2021 we will have a special edition looking at the use of radiopharmaceuticals. Radiopharmaceutical therapy is emerging as a safe and effective targeted approach to treating many types of cancer. Novel therapeutic radiopharmaceuticals are being developed at an impressive rate and are intended to tackle both the diagnosis and treatment of a disease with a single agent. Radiopharmaceutical dosimetry is also currently in its infancy but has the potential to transform the field in the same way it did for external beam radiation therapy.
Find out more(opens in new tab/window) | Send your pre-submission query(opens in new tab/window)
Evolving Threats in Cybersecurity and Radiation Oncology
In the weeks leading up to the national elections in November of 2020, while much of our nation's attention was focused on political issues, there were a series of cyberattacks on U.S. Healthcare institutions. The U.S Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, along with the Federal Bureau of Investigation, and the Cybersecurity and Infrastructure Safety Agency issued an advisory on October 28, 2020, noting that "CISA, FBI, and HHS have credible information of an increased and imminent cybercrime threat to U.S. hospitals and healthcare providers."
Find out more(opens in new tab/window) | Send your pre-submission query(opens in new tab/window)
Biosafety & Health
There are currently 3 special issues open for submission.
Enterovirus infections and health
Human enterovirus comprises more than 100 serotypes, causing a wide range of diseases. Poliomyelitis is believed to be an ancient disease, but the currently importation of wild poliovirus and the circulation of VDPV2 still pose a threat to polio-free countries. Epidemics and outbreaks caused by nonpolio enteroviruses remains an important public health problem as well, such as acute flaccid paralysis, aseptic meningitis, encephalitis, hand, foot, and mouth disease, acute hemorrhagic conjunctivitis, etc. To protect human health and safety from the threat of enterovirus diseases, new technology and findings from epidemiology, molecular biology, immunology, and bioinformatics are needed to address the emerging issues, such as: genomic and biological characterization of novel enteroviruses; viral infection mechanisms; origin, transmission, prevalence, and evolution of emerging and re-emerging enterovirus; rapid diagnostic method; vaccine development and efficiency; clinical and environmental surveillance systems and early warning; etc. The aim of this special issue is to provide a platform for high quality researches regarding the above topics to support prevention and control of enterovirus diseases.
Guest Editors:
Professor Yong Zhang, Chinese Center for Disease Control and Prevention
Professor Zexin Tao, Shandong Center for Disease Control and Prevention
Professor Jing Lu, Guangdong Provincial Institute of Public Health
Find out more(opens in new tab/window)
Forecast the potential SARS-CoV-2 variants in the future and predict their biological properties and social impacts from bioinformatics and public health perspectives
SARS-CoV-2 keeps evolving. There will be other emerging SARS-CoV-2 variants in the future. Can we predict what variants are most likely to emerge? Are we prepared for another outbreak? Is it possible to predict their biological properties? Can we predict their transmissibility, incidence rate and death rate? Will we be protected from them with current vaccines? Although more than two years have passed since the outbreak of COVID-19, we still can't answer these questions quickly enough to avoid the disasters caused by the delta, omicron SARS-CoV-2 variants. We need to prepare in advance by forecasting the evolution path of SARS-CoV-2, identifying the most likely SARS-CoV-2 variants in the future and predicting their biological properties. In this special issue, we will try to forecast the SARS-CoV-2 evolution from different perspectives. What's more, we will integrate the multi omics data, such as the genomics of SARS-CoV-2 variants, transcriptomics of SARS-CoV-2 infection, single cell transcriptomics during vaccination and drug treatment, and public health data, such as pathogen, hosts, environment, human economic activity, medical care, to get a comprehensive view of how new SARS-CoV-2 variants may affect the transmissibility, pathogenicity and fatality, and organize epidemic prevention and control.
Guest Editors:
Yixue Li, Guangzhou Laboratory
Yuming Guo, Monash University
Tao Huang, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences
Find out more(opens in new tab/window)
Biosafety and Immunity
Emerging and reemerging infectious diseases, as evidenced by the current COVID-19 pandemic, has raised concerns on biosafety worldwide. Interdisciplinary studies between biosafety and immunity is relevant in many issues, such as vaccine and monoclonal antibody development, herd immunity, and immunopathology. Meanwhile, advances in immunological sciences and technology are developing rapidly, resulting in important recent research achievements. In addition, biosafety and biosecurity issues, especially those related to immunity, are an important topic for consideration . The special issue “Biosafety and Immunity” is organized based on communicating the interdisciplinary topics related to biosafety and immunology in a timely manner. The use of new theories, methods and products from the field of immunology will help eliminate biosafety threats and prevent biosafety hazards, especially with regards to infectious diseases. Interdisciplinary studies related to biosafety and immunology hold great promise to protect human health and safety from the threat of emerging and reemerging diseases.
Guest editors:
Prof. William J. Liu, Chinese Center for Disease Control and Prevention
Prof. Gary Wong, Institute Pasteur of Shanghai, Chinese Academy of Sciences
Prof. Yanyi Wang, Wuhan Institute of Virology, Chinese Academy of Sciences
Dr. Hui Li, China-Japan Friendship Hospital
Cancer Treatment and Research Communications | Translational Oncology
Non-coding RNA in Cancer
Over recent decades, next-generation RNA sequencing advances have become overly convenient to measure gene expression levels and explore new transcriptional units across the transcriptome.
Up to 80% of the human genome encodes a large number of non-coding RNAs (ncRNA), which have been emerged as critical regulators instead of junk RNAs in different disease processes. ncRNAs (including miRNAs, lncRNAs and circRNAs) are gaining widespread attention for their abundance in number, expression specificity, functional roles in diseases, and potential clinical applications. This special issue will focus on the ncRNAs in various cancer types particularly miRNA, lncRNAs and circRNAs.
Guest Editor:
Dr. Yongyong Yang, Northwestern University, Chicago, IL, USA
Intelligent Medicine
There are currently 3 special issues open for submission.
Artificial Intelligence and Radiomics in Medical Imaging
With the rapid development of medical imaging techniques, artificial intelligence (AI) and radiomics have been heralded as the frontiers in medical imaging (MI). AI in MI is the science and engineering of making intelligent imaging machines, especially intelligent computer programs for clinical practices. While the radiomics refers to the high-throughput extraction of a large number of imaging and genetic features from multi-modality data sets and characterizes the region of interests (ROIs) for further analyses of grading, classification, predication, planning and prognosis assessment. The ultimate goal of AI and Radiomics in MI is to improve patient outcomes for better prevention, diagnosis, and treatment of diseases. Therefore, the aim of this special issue is willing to provide the readers with an up-to-date research progress and future development of this field in order to help improve human health. According to these premises, this issue is soliciting manuscripts addressing topics including original articles and review articles on the related aspects of “AI and radiomics in MI”.
Guest Editor:
Professor Tao Wu, Shanghai University of Medicine and Health Sciences
Find out more(opens in new tab/window)
Ethical, Legal, and Social Implications
Ethical, Legal, and Social Implications (ELSI), a new column in Intelligent Medicine that invites interdisciplinary perspectives on the social, ethical, legal, and responsibility aspects of the use of artificial intelligence (AI) in medicine and health care. Papers in this column will examine the practical, conceptual, and policy dimensions of the use of AI for health-related purposes from comparative and international perspectives. We invite contributions from around the world in all application areas of AI for health, including health care, health research, drug development, healthcare system management, as well as public health and public health surveillance. The column aims to provide a forum for reflective and critical scholarship that contributes to the ongoing academic and policy debates about the development, use, governance, and implications of AI in medical and health care settings.
Guest Editors:
Prof. Xinqing Zhang, Peking Union Medical College & Chinese Academy of Medical Science
Prof. Achim Rosemann, De Montfort University
Find out more(opens in new tab/window) | Send your pre-submission query(opens in new tab/window)
Intelligent Prevention and Control of Emerging Infectious Diseases
Given the crucial role artificial intelligence and big data technology play in the prevention and control of the COVID-19 global outbreak, Intelligent Medicine, an English journal owned by the Chinese Medical Association, intends to launch a special issue and column on “Intelligent Prevention and Control of Emerging Infectious Diseases” to comprehensively report the latest progress in this field. The publication now calls for contributions from experts, scholars, and industry professionals in the field of research on emerging infectious diseases.
Based on big data and artificial intelligence technology, the special issue covers, but is not limited to, surveillance and early warning of emerging infectious diseases, epidemic prevention and control and analysis of epidemiological investigation, epidemic simulation, disease modeling, research and development of vaccine and drug, etc. The contribution can be in the form of Editorial/Original Article/Review Article, with a word limit around 6000 words (with a certain flexibility), and an abstract and references, as specified in the Journal’s Guide for Authors.
International Journal of Radiation Oncology - Biology - Physics
Call for Papers: Oligometastases
Since the 1990s, oncologists have increasingly recognized the unique phenomenon of oligometastatic disease.
This is a metastatic cancer state that is thought to be controllable if not curable by appropriately delivered combinations of systemic and local ablative therapies, as compared to widespread, disseminated metastasis. However, standard definitions and the proper application of therapies remain topics of active debate, with high likelihood that these may differ across histologies and mode of presentation. The Red Journal proposes an in-depth examination of all aspects of oligometastasis as approached by the clinic, biology, and physics, with the aim of publishing a focus issue devoted to the subject in the latter half of 2022.
Leukemia Research
Clonal Hematopoiesis
Clonal hematopoiesis (CH) is defined by the acquisition of somatic leukemia associated driver mutations in hematopoietic stem and progenitor cells, with the potential for subsequent expansion over time.
CH is associated with an increased risk of both myeloid and lymphoid malignancies, and also with increased all-cause mortality, largely due to endothelial dysfunction and cardiovascular disease. Clonal selection pressures that drive clonal progression remained to be adequately defined. However, exposures to alkylating agents, ionizing radiation, radioisotope therapy, environmental carcinogens including tobacco and increasing age with defective DNA replication and repair, increase the risk for progression and transformation to hematological neoplasms. CH is also encountered in the context of bone marrow failure syndromes, where it may be a form of maladaptive hematopoietic rescue, reducing the extent and severity of cytopenias, however, increasing the risk of myeloid neoplasms. While biology of CH continues to be defined, early intervention strategies remain primitive. Apart from known risk factor modification for cardiovascular/cerebrovascular disease and clonal progression, intervention strategies based on the type of mutations and the inflammatory milieu that results in propagation are much needed. In this issue of the Journal, we attempt to address these topics.
Guest Editor:
Dr. Mrinal Patnaik, Mayo Clinic
Neoplasia
There are currently 3 special issues open for submission.
Pediatric Brain Tumors: Reviews and Current Studies from the Children’s Brain Tumor Network (CBTN)
Pediatric brain tumors are the most common solid tumor of childhood and are now the leading cause of disease-related death in this age group. Fortunately, translational research in this area is expanding rapidly. In this special issue, we focus on the current state of translational and clinical research in pediatric neuro-oncology, with a special focus on leading international clinicians and researchers working with the Children’s Brain Tumor Network (CBTN), the world’s largest brain tumor biorepository.
Guest Editors:
Dr. Carl Koschmann, University of Michigan
Dr. Michael Prados, UCSF
Send us your pre-submission query(opens in new tab/window)
The Microbiome and Cancer
This Special Issue in Neoplasia(opens in new tab/window) explores the expanding role of the microbiome – the complex interaction of microorganisms that possess a commensal, symbiotic, or pathobiont relationship with its host –in the process of cancer initiation, progression, and treatment. Investigation of the relationship of the microbiome with cancer is rapidly progressing from observational studies to an area of research that holds great promise for prevention, diagnosis, and therapy. This collection takes an encompassing view of this emerging field and welcomes articles at the intersection of biology, data science, technology, and clinical applications.
Guest Editor:
Ryan M. Thomas, MD(opens in new tab/window), University of Florida, USA
Send us your pre-submission query(opens in new tab/window)
Challenges in synergizing radiation and immunotherapy
Synergizing radiation and immunotherapy is an attractive approach to treat tumors. To harness the complex, non-linear mechanisms of tumor-immune interactions and tumor growth and treatment response dynamics require discussions across scientific disciplines. This Special Issue at Neoplasia covers the latest developments on the synergy of radiation and immunotherapy across multiple disciplines: radiation oncology, radiobiology, immunology, cancer biology and mathematical, computational and systems biology.
Guest Editors:
Heiko Enderling(opens in new tab/window), Moffitt Cancer Center, Florida, USA
Udo Gaipl, Translational Radiobiology, Department of Radiation Oncology, University Hospital Erlangen, Germany
Markus Hecht, Translational Immuno-oncology, Department of Radiation Oncology, University Hospital Erlangen, Germany
Technical Innovations & Patient Support in Radiation Oncology
Patient-centred supportive care: focus on optimizing personalized care in clinical radiation oncology
Through decades the delivery of radiotherapy has been optimized with novel techniques and technologies.
The more personalized treatments in radiation oncology makes individual needs assessments essential to ensure and optimize timely patient-centered care. Increasing possibilities within telehealth also provides new ways of delivering supportive care to patients receiving radiotherapy. Thus, the aim of this special issue is to focus on research investigating how to optimize supportive care in radiotherapy.
Guest Editors:
Pia Krause Møller, RTT, MPH, Odense University Hospital
Dr. Gillian Prue, Queen’s University
Translational Oncology
There are currently 9 special issues open for submission.
Cytokines in Immunotherapy
This Special Issue explores the complex role of cytokines as immune mediators in the context of cancer. It welcomes basic and translational reports on the immunobiology of cytokines, interactions with immune cells and the tumor microenvironment, and development of cytokine-based drugs, as well as clinical reports on the use of cytokines in current immunotherapy protocols.
Guest Editor:
Prof. Dr. Vladimir Jurisic, University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
Send us your pre-submission query(opens in new tab/window)
Geriatric Oncology
Older patients are often underrepresented in clinical trials that form the standard of cancer care. While most older patients gain similarly as the younger patients from treatment, they are at higher risk for toxicities and worse complications. Specific studies on the treatment efficacy and safety, as well as the diverse biology of the disease in older patients are an area of unmet need, as the pharmacokinetics, pharmacodynamics, as well as the molecular landscape may be different due to aging.
Guest Editors:
Dr. Anna Rachelle Mislang, Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University
Dr. Nicolò Matteo Luca Battisti, The Royal Marsden NHS Foundation Trust, Breast Cancer Research Division, The Institute of Cancer Research
Send us your pre-submission query(opens in new tab/window)
Metabolic Reprogramming and Cancer Progression
Cancer cells are surrounded by a different microenvironment than that of normal cells and therefore must exhibit rapidly adaptive responses to hypoxia and hypo-nutrient conditions. The changes of tumor cellular bioenergetics, called “metabolic reprogramming,” has been recognized as a hallmark of cancer. It is highly challenging to develop therapies that exploit metabolic vulnerabilities due to the metabolic heterogeneity among human tumors. Increasing studies demonstrate that the metabolic properties and preferences of a tumor change during cancer progression. This produces distinct sets of vulnerabilities between primary tumors and metastatic cancer, even in the same patient or experimental models.
Publications in this special issue aim not only to collect the emerging concepts about metabolic reprogramming in cancer, with particular attention on why metabolic properties evolve during cancer progression, but also to determine how this information might be used to develop better therapeutic strategies.
Guest Editors:
Dr. Ziyi Liu, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Maryland, USA
Dr. Nabin Poudel, University of Virginia Health System, Charlottesville, Virginia, USA
Dr. Qinan Yin, College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, Henan, 471000, China
Send us your pre-submission query(opens in new tab/window)
Frontier in cellular immunotherapy of solid tumors
Cell therapy has emerged as a promising therapeutic approach for solid tumors. Now the most cell types included T cells, tumor-infiltrating lymphocyte, natural killer cells, natural killer T cells, dendritic cells, and mesenchymal stromal cell. The main modified method were engineered T cell receptor(TCR) and chimeric antigen receptor(CAR). It is important to discuss the different approaches, challenges, and further directions of adoptive cell transfer in solid tumors. Thus, the aim of this Translational Oncology special issue is to provide such platform, which is fully within the scope of the Journal.
Guest Editors:
Dr. Jun Lu; Oncology Department, Beijing Youan Hospital, Beijing, China
Dr. Fang Xiong; Oncology Department, Beijing Youan Hospital, Beijing, China
Send us your pre-submission query(opens in new tab/window)
Biomaterials in Cancer Research
Cancer tumors can be rapidly created by the activity and development of abnormal cells beyond their usual boundaries, which can further spread to the other tissues and organs. Recent advancements suggested that biomaterials can offer practical solutions for cancer research during different stages from early diagnosis to control and treatment of tumors. Biomaterials also help targeted delivery of drugs to the tumor microenvironment. Extensive research is being undertaken to explore the potential of advanced biomaterials for targeting, treating, and preventing cancer. This special issue discusses the role and potential of advance biomaterials in cancer research.
Guest Editor:
Dr. Masoud Mozafari, University of Toronto
Send us your pre-submission query(opens in new tab/window)
Tumor microenvironment: Emerging discoveries and potential targeting strategies
The tumor microenvironment (which consists of the ECM plus “normal” cells such as fibroblasts, endothelial cells, macrophage, lymphocytes and others) supports the cancer cells within the tumor to proliferate and invade the neighboring tissues. A plethora of immune cell intrusion and mechanical changes occur in this environment for sustaining primary and metastatic tumor growth. In this issue, we focus on all aspects of tumor microenvironment that support oncogenic growth and survival.
Guest Editor:
Dr Sayan Chakraborty, Institute of Molecular and Cell Biology, A*STAR, Singapore
Send us your pre-submission query(opens in new tab/window)
Emerging field of single cell technologies leading to comprehensive understanding of biology
This special issue will cover single cell technologies and their recent contribution to basic as well as translational research.
Guest Editor:
Dr. Pankaj Dwivedi, Genentech, Inc
Send us your pre-submission query(opens in new tab/window)
Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer
The successful use of immune checkpoint blockers in cancer accelerated research on the regulatory function of co-inhibitory checkpoint proteins. This Special Issue in Translational Oncology(opens in new tab/window) focuses on the role of co-inhibitory checkpoint proteins, including members of the CD28-, B7-, and TNF/TNFR-families in tumor immunity, as well as in the regulation of tumor microenvironment, increased tumor malignancy, and contribution to therapy resistance. The issue also covers the relevance of co-inhibitory checkpoint proteins as new biomarkers and therapeutic targets.
Guest Editor:
Caroline Nunes-Xavier, PhD(opens in new tab/window), Institute for Cancer Research, Oslo University Hospital, Norway
Send us your pre-submission query(opens in new tab/window)
COVID-19 and Cancer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease 2019 (COVID-19) brought an unprecedented level of global disruption. Its impact on the management of cancer patients depends heavily on the timely dissemination and integration of interdisciplinary research being conducted internationally. This Special Issue in Translational Oncology(opens in new tab/window) welcomes reports on basic, translational, and clinical studies on outcomes, vaccines, therapy, and trials that can help advance our understanding of how these diseases intersect.
Guest Editor:
Vivek Subbiah, MD(opens in new tab/window), MD Anderson Cancer Center, USA
Recently Published
Physics & Imaging in Radiation Oncology
Practical Radiation Oncology
Advances in Radiation Oncology
Biosafety and Health
Journal of the National Cancer Center
Cancer Letters
Clinical Breast Cancer
Clinical Colorectal Cancer
Cancer Treatment and Research Communications
Journal of Bone Oncology
Leukemia Research Reports
Surgical Oncology
Translational Oncology
Current Problems in Cancer
Seminars in Oncology
Seminars in Radiation Oncology
Elsevier’s Oncology Journal Network
We’ll help you find the right home for your research – fast
With over 50 journals, including The Lancet Oncology, Cancer Cell, European Journal of Cancer and Cancer Letters, Elsevier’s Oncology Journal Network has the right fit for your paper.
Article Advance
Your paper, our priority
Article Advance ensures a fast, seamless publication process and offers additional support from a dedicated editorial team.
